RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer and prostate cancer, announced its financial results for the quarter ended September 30, 2011.
